Clinical Trial Update: Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Erlotinib in combination with OSI-906 in adults with advanced non-small cell lung cancer carrying activating EGFR mutations; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• OSI-906 (OSI-906)
• Tarceva (erlotinib)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: NSCLC, Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED